Phase 1/2 × Myelodysplastic-Myeloproliferative Diseases × 1 year × Clear all
NCT06523556 2026-03-13

Axatilimab With or Without Azacitidine for the Treatment of Patients With Advanced Phase Myeloproliferative Neoplasms, Myeloproliferative Neoplasm/Myelodysplastic Syndrome Overlap or High Risk Chronic Myelomonocytic Leukemia

Ohio State University Comprehensive Cancer Center

Phase 1/2 Recruiting
52 enrolled
NCT02158858 2025-10-08

A Phase 1/2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Hematologic and Myeloproliferative Malignancies

Constellation Pharmaceuticals

Phase 1/2 Completed
336 enrolled